PHC
28.4.2022 12:07:18 CEST | Business Wire | Press release
PHC Holdings Corporation (hereafter PHC Group) (TOKYO:6523) today announced the appointment of Shoji Miyazaki as the company’s Chief Executive Officer. He succeeds John Marotta, who has stepped down as the company’s CEO and Representative Director and also from the Board of Directors effective April 28, 2022. Shoji Miyazaki remains a Representative Director on the company’s Board of Directors.
Shoji Miyazaki was previously PHC Group's Chief Operating Officer and former President of PHC Corporation and brings more than 30 years of experience at PHC Group and Panasonic. He joined Matsushita Kotobuki Electronics Co., Ltd. a predecessor of PHC Corporation in 1990, upon graduation. In 2001 he moved to Panasonic’s healthcare medical business unit, focusing on medical diagnostics, where he continued in numerous roles before being appointed Executive Vice President and COO of PHC Holdings Corporation in 2020. At the same time he also held Board positions at PHC Corporation and LSI Medience Corporation.
“I look forward to focusing on efficiency and integration, building on the work our team has delivered integrating our teams and portfolio since the acquisitions of Epredia and LSI Medience in 2019. Delivering value for patients, clinicians, business partners and shareholders remains PHC Group’s top priority,” commented Shoji Miyazaki.
In addition, effective July 1, 2022, Board Member Koichiro Sato will join PHC Group as Chief Operating Officer. On the same date, subject to approval of the proposal for election of directors at the General Meeting of Shareholders, he will become a Representative Director. His main responsibility will be overseeing company operations outside of Japan, where half PHC Group’s business and employees are located, including Ascensia, Epredia, and PHCbi NA and EU. Sato joins PHC Group from his current role as Chief Executive Officer in the Hong Kong Branch of MBK Healthcare Management Pte. Ltd. and he brings nearly 25 years of experience to PHC Group from his international career within Mitsui & Co. related companies. He entered the healthcare field in 2016 as a general manager in the Mitsui healthcare business division.
“We are pleased to welcome Shoji Miyazaki as PHC Group’s new CEO. He has a strong track record of leading global teams across diagnostics, life sciences, and diabetes, and is particularly well suited to driving the next leg of innovation from PHC Group. We continue to be committed to creating healthcare solutions that improve lives and strengthen our communities,” said Kyoko Deguchi, External Director.
“PHC Group looks forward to advancing our medium- and long-term plans to deliver global growth, innovation, efficiency, and performance, and to continue contributing to a healthier society. We thank John for his concentrated efforts on bringing the company to the IPO, streamlining and integrating the organization, and bringing consistency to PHC Group’s management systems and structures. We wish him all the best,” continued Ivan Tornos, External Director.
About PHC Holdings Corporation (PHC Group)
PHC Holdings Corporation (TOKYO:6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia, and LSI Medience Corporation. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2020 were JPY 306 billion with global distribution of products and services in more than 125 countries.
www.phchd.com/global
www.phchd.com/global/news/2022/0428
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005524/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom